SOUTH SAN FRANCISCO, Calif., June 6 /PRNewswire-FirstCall/ -- Renovis,
Inc. (Nasdaq: RNVS), today announced that Corey S. Goodman, Ph.D.,
President and Chief Executive Officer, will be presenting at the Goldman
Sachs Annual Healthcare Conference at The Ritz Carlton in Laguna Niguel,
California. The presentation will be webcast live via the internet on June
13, 2006 at 2:00 p.m. EDT. Additionally, John C. Doyle, Chief Financial
Officer, will be presenting a corporate update at the Needham & Company
Annual Biotechnology and Medical Technology Conference at the New York
Palace Hotel in New York City. The presentation will be webcast live via
the internet on June 14, 2006 at 11:30 a.m. EDT. To access the live
webcasts, please visit Renovis' homepage, http://www.renovis.com. An
archived version of each webcast will be available in the same location for
seven days following the presentation.
About Renovis
Renovis is a biopharmaceutical company primarily focused on the
discovery and development of drugs for neurological diseases and disorders
in areas of unmet medical need. Our most advanced product candidate,
NXY-059, is in Phase III clinical trials for acute ischemic stroke with our
exclusive licensee, AstraZeneca AB. NXY-059 has a proposed mechanism of
action of free radical trapping. It is being studied as a neuroprotectant
in clinical trials based on effects seen in experimental models of acute
ischemic stroke. In addition to proprietary research programs in the areas
of cytoprotection, pain and inflammation, Renovis has a worldwide
collaboration and license agreement with Pfizer to research, develop and
commercialize small molecule VR1 antagonists, and a research and
development collaboration with Genentech to discover and develop
anti-angiogenesis drugs and drugs that promote nerve re-growth following
nervous system injury.
For additional information about the company, please visit
http://www.renovis.com.
Safe Harbor Statement
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that
involve substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, future operations, future financial position, plans and
objectives of management are forward-looking statements. We may not
actually achieve these plans, intentions or expectations and Renovis
cautions investors not to place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements we make. Various important factors that could cause actual
results or events to differ materially from the forward- looking statements
that we make are described in greater detail in the "Risk Factors" section
of our Quarterly Report on Form 10-Q, which was filed with the Securities
and Exchange Commission on May 9, 2006, and our Annual Report on Form 10-K,
which was filed with the Securities and Exchange Commission on March 14,
2006. We do not assume any obligation to update any forward-looking
statements.
Contacts:
INVESTORS: MEDIA:
Renovis, Inc. Noonan Russo
John C. Doyle David Schull
(650) 266-1407 (858) 546-4810
doyle@renovis.com david.schull@eurorscg.com
SOURCE Renovis, Inc.
 back to top
Related links:
http://www.renovis.com
CONTACT:
INVESTORS: John C. Doyle of Renovis, Inc.,
+1-650-266-1407, doyle@renovis.com; or MEDIA: David Schull of
Noonan Russo, +1-858-546-4810, david.schull@eurorscg.com
|
